Clinical trials: Autoimmune Disorder
Rheumatoid Arthritis
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for…
- Trial name
- NCT00124982
- Testing
- Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy
- Where
- 148 sites in United States, Belgium and 8 more
- Volunteers
- 1,286 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis
Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II
The hypothesis is that Polyphenon E can protect brain cells in patients with Multiple Sclerosis. To test this hypothesis we are going to compare the changes in n-Acetyl-Aspartate (a chemical that reflects the number of neurons…
- Trial name
- POEMS (NCT01451723)
- Testing
- Polyphenon E
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Chronic Inflammatory Demyelinating Polyneuropathy
Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Participants will be requested to deliver non-invasive vagus nerve stimulation (nVNS) two times per day, at least five days per week.
- Trial name
- NCT03772717
- Testing
- Non-invasive vagus nerve stimulation (nVNS), Standard of care treatment
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 1
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, and to measure the quantity of LY2605541 in fat…
- Trial name
- NCT02109029
- Testing
- Insulin Peglispro, Human Insulin
- Where
- Austria
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms
Objective: to gain experience with in-home use of a modified algorithm that will dose insulin to minimize projected hyperglycemia overnight in addition to suspending the pump if hypoglycemia is projected overnight and to obtain…
- Trial name
- PHM2 (NCT02438189)
- Testing
- Predictive Hyperglycemia Minimization Algorithm, Predictive Hypoglycemia Minimization Algorithm
- Where
- 3 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- Jaeb Center for Health Research
Systemic Lupus Erythematosus
Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
Hypothesis: A reason for repeated disappointing outcomes of clinical trials testing targeted immune biologics for lupus may be the heterogeneity of the disease, exacerbated by the variable effects on immune homeostasis of the…
- Trial name
- BOLD (NCT00987831)
- Testing
- Group B SLE one blood donation, Blood drawing only Group C, Group A SLE prospective study
- Where
- 2 sites in United States
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Oklahoma Medical Research Foundation
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen
Type 1 Diabetes Mellitus
Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes
The overall purpose of this trial is to assess the efficacy and safety of using oral verapamil in subjects with recent onset T1D in order to downregulate TXNIP and enhance the patients' endogenous beta cell mass and insulin…
- Trial name
- NCT02372253
- Testing
- Verapamil
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
Healthy
Study of Belimumab Administered Subcutaneously to Healthy Subjects
The purpose of this study is to measure the amount of belimumab in the blood when given as an injection under the skin (subcutaneously; SC) and to evaluate the safety and tolerability of multiple injections under the skin in…
- Trial name
- NCT01583530
- Testing
- Single Dose Group: Belimumab IV 240 mg, Single Dose Group: Belimumab SC 2 x 120 mg, Single Dose Group: Belimumab SC 1 x 240 mg
- Where
- 4 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Human Genome Sciences Inc.
Rheumatoid Arthritis
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
To compare the maintenance of efficacy of the combination of etanercept 50 mg once weekly plus methotrexate with or without other disease modifying antirheumatic drugs therapy with that of methotrexate with or without other…
- Trial name
- NCT01578850
- Testing
- Etanercept
- Where
- 62 sites in Brazil, China and 17 more
- Volunteers
- 491 people
- Sponsor
- Pfizer
Relapsing Remitting Multiple Sclerosis
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
Teva is developing a 40 mg/ml GA Injection, administered once daily under the skin, for the treatment of R-R MS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the…
- Trial name
- NCT00337779
- Testing
- Glatiramer Acetate (GA) 40 mg, glatiramer acetate 20 mg
- Volunteers
- 1,155 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)
The purpose of this study is to investigate the impact of ankle foot orthoses (AFOs) on the spatial and temporal gait parameters, electromyography (EMG), walking endurance, and quality of life in select individuals living with…
- Trial name
- NCT01947582
- Testing
- Ankle foot orthosis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Texas Southwestern Medical Center
Type 1 Diabetes
Two Way Crossover Closed Loop Study R-AP vs MPC
An artificial pancreas (AP) is a control system for automatic insulin delivery. The investigators have implemented a missed meal bolus detection algorithm for use within an AP control system.
- Trial name
- NCT05083559
- Testing
- MPC AP algorithm, Robust R-AP algorithm
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Oregon Health and Science University
Chronic Thrombocytopenia, Immune Thrombocytopenia
Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)
Core Study: To demonstrate that the efficacy of avatrombopag (in addition to standard of care) is superior to placebo (in addition to standard of care) for the treatment of adult participants with chronic immune thrombocytopenia…
- Trial name
- NCT01438840
- Testing
- Avatrombopag, Standard of care
- Where
- 25 sites in Australia, Belgium and 9 more
- Volunteers
- 49 people
- Sponsor
- Eisai Inc.
Systemic Lupus Erythematosus
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
The purpose of this study is to determine whether CC-220 is effective for the treatment of skin, joint and serological manifestations of systemic lupus erythematosus.
- Trial name
- NCT02185040
- Testing
- CC-220
- Where
- 35 sites in United States
- Volunteers
- 42 people
- Sponsor
- Celgene
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)
This 3 arm study will compare the safety and efficacy, with respect to a reduction in signs and symptoms and prevention of joint damage, of tocilizumab versus placebo, both in combination with methotrexate (MTX) in patients with…
- Trial name
- NCT00106535
- Testing
- tocilizumab [RoActemra/Actemra], Methotrexate
- Where
- 152 sites in United States, Australia and 14 more
- Volunteers
- 1,196 people
- Sponsor
- Hoffmann-La Roche
Relapsing Remitting Multiple Sclerosis
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Phase 1 study to assess the safety and biological activity of ATX-MS-1467 in patients with relapsing forms of multiple sclerosis.
- Trial name
- NCT01097668
- Testing
- ATX-MS-1467
- Where
- 16 sites in Russia, United Kingdom
- Volunteers
- 43 people
- Sponsor
- Apitope Technology (Bristol) Ltd.
Arthritis, Rheumatoid
Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients
This study is to evaluate available local data in Iraqi patients with rheumatoid arthritis on Enbrel treatment with regards to the impact of Rheumatoid factor and Anti-cyclic citrullinated peptide using data from the Baghdad…
- Trial name
- NCT04428424
- Testing
- Enbrel
- Where
- Iraq
- Volunteers
- 1,493 people
- Sponsor
- Pfizer
Uveitis
Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis
The purpose of this study is to explore the efficacy of Norflo Oro in the treatment of relapsing autoimmune uveitis (RAU), measured as a long term reduction of the frequency and the severity of relapses, in patients with HLA-B27…
- Trial name
- NCT03584724
- Testing
- Norflo Oro
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Eye Pharma
Systemic Lupus Erythematosus
A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (SC) to adult subjects with Systemic Lupus Erythematosus (SLE).
- Trial name
- BLISS-SC (NCT01484496)
- Testing
- Belimumab 200 mg SC, Standard therapy
- Where
- 207 sites in United States, Argentina and 29 more
- Volunteers
- 839 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.